Chugai Pharmaceutical Co Ltd (4519.T)
6,790JPY
19 Apr 2019
¥40 (+0.59%)
¥6,750
¥6,950
¥6,960
¥6,760
521,900
889,974
¥7,880
¥5,430
Latest Key Developments (Source: Significant Developments)
Alexion Opposes Claims Against Co Filed By Chugai Pharmaceutical
Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::ALEXION - RESPONDING TO COMPLAINT FILED AGAINST CO BY CHUGAI PHARMACEUTICAL, CO TO OPPOSE CLAIMS & TO PROCEED WITH BUSINESS PLANS FOR ALXN1210. Full Article
Chugai Pharmaceutical says waiver of claims in patent infringement lawsuit
April 11 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it has decided to waive its claim in a patent infringement lawsuit against Nippon Kayaku Co Ltd <<<4272.T>>>.Says co filed a lawsuit to the Tokyo District Court on Aug. 17, 2017, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® Injection 60 and 150 (Herceptin® Injection) against Nippon Kayaku, the applicant for marketing approval of the biosimilar of Herceptin® Injection, citing such party's infringement of the application patents for the treatment of breast cancer owned by Genentech Inc. Full Article
CHUGAI PHARMACEUTICAL says filing of patent infringement lawsuit and petition for provisional disposition order
Jan 9 (Reuters) - CHUGAI PHARMACEUTICAL Co Ltd <4519.T> ::Says it filed an application for assisting intervention with Zenyaku Kogyo Co Ltd in a lawsuit that Genentech Inc filed, wherein the plaintiff demands prohibition of sales etc. of Rituxan® Injection, against Sandoz K.K and Kyowa Hakko Kirin Co Ltd.Says the company has also filed an application for assisting intervention in a petition for provisional disposition order that has been filed with the lawsuit. Full Article
Chiome Bioscience says termination of joint research contract
Dec 18 (Reuters) - Chiome Bioscience Inc <4583.T>:Says it announces termination of candidate antibody related joint research contract, which was signed between the co and CHUGAI PHARMACEUTICAL CO LTD <<<4519.T>>>, as the contract has expired on Dec. 31 . Full Article
Chugai Pharmaceutical says change of chief executive officer
Dec 12 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it names current president and chief operating officer Tatsuro Kosaka as chief executive officer and president, effective late March 2018. Full Article
R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I
Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I.Says rating outlook stable -R&I. Full Article
Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma
Nov 14 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it and TAIYO HOLDINGS CO LTD <<<4626.T>>> announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd., a wholly owned subsidiary of Taiyo Holdings. Full Article
Chugai Pharmaceutical says lawsuit on patent infringement concerning Herceptin® injection and petition for provisional disposition order
Sept 8 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says co has filed a lawsuit and a petition for provisional disposition order against Nippon Kayaku Co.,Ltd <<<4272.T>>>, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® injection 60 and 150 (Herceptin® injection) .Genentech Inc, a U.S.-based firm, is a patent holder and co is the exclusive licensee of Herceptin® injection .Says co and Genentech are the co-plaintiff of the lawsuit. Full Article
Chugai Pharmaceutical aims to increase core oper profit to more than 100 bln Yen in year ending Dec. 2019 - Nikkei
Aug 21 (Reuters) - Nikkei::Chugai Pharmaceutical Co Ltd aims to increase its core operating profit to more than 100 billion yen ($920 million) in the year ending December 2019 - Nikkei. Full Article
Chugai Pharmaceutical sells trusted beneficial rights of property
May 12 (Reuters) - Chugai Pharmaceutical Co Ltd <1491.T>: :* Says it has sold the trusted beneficial rights of Tokyo-based property on May 12. Full Article
Earnings vs. 
Estimates